Early cancer detection startup Craif raises $22M

Early cancer detection startup Craif raises $22M

Cancer ranks as one of the top causes of death worldwide. The National Cancer Institute reported nearly 20 million new cancer cases and 9.7 million

Japanese startup ‘Craif’ raises US$22M to bring urine cancer biopsy to the U.S.

A startup spun out from a Japanese university has raised US$22 million to propel expansion of its proprietary multi-cancer urine biopsy in the United States. The “miSignal” test has been available throughout pharmacies and medical centres in Japan since 2022. Craif founder and chief executive Ryuichi Onose just made the funding reveal in an interview with TechCrunch. His biotech company has raised US$57 million to date and now has a valuation ju…

Startup, Craif, Secures $22M to Advance Early Cancer Detection

Cancer remains one of the world’s deadliest diseases. In 2022, the National Cancer Institute reported nearly 20 million new cases and 9.7 million deaths globally.  And by 2040, this number could soar to almost 30 million. To tackle this increasing issue, Craif is stepping up. Craif’s Vision Founded in 2018 as a spin-off from Nagoya […] The post Startup Craif Secures $22 Million to Advance Early Cancer Detection appeared first on AutoGPT.

CoinStats - Early Cancer Detection Startup Craif Secures ...

In the dynamic world of tech and investment, innovation in healthcare is constantly pushing boundaries. A prime example is the significant funding round recently closed by Craif, a Japanese Biotech Startup focused on revolutionizing Early Cancer Detection. This news highlights the continued interest in medical technology that promises non-invasive and more accessible diagnostic tools. Revolutionizing Detection: What Technology Does Craif Use? Ca…

BLK ALERTS - Early cancer detection startup Craif raises $22M

Cancer ranks as one of the top causes of death worldwide. The National Cancer Institute reported nearly 20 million new cancer cases and 9.7 million cancer-related deaths globally in 2022, with projections showing a rise to 29.9 million new cases by 2040. Craif, spun off from Nagoya University in Japan in 2018, is using microRNA(miRNA) […]

Craif raises $22 million to bring AI cancer tests to the US

Craif, a Japanese startup developing an AI-powered early cancer detection software, has raised $22 million in Series C funding, bringing its total raised to $57 million. The funding round was led by existing investor X&KSK and included new investors Unreasonable Group, TAUNS Laboratories, Daiwa House Industry, and Aozora Bank Group. The company, spun off from Nagoya University in 2018, uses microRNA (miRNA) to detect cancer at an early stage thr…